Publisert 21.12.2020
EGM January 4th 2021
January 4th 2021
Extraordinary Annual Meeting January 4th 2021. (Video/phone)
(only one agenda point: VPS registration of shares)
Notice EGMRegenics AS have developed clinical proof of efficacy and safety in human 2 degree burn wounds for our products Collex® and Vernex®.
The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.
